Hydroxyurea Treatment of Meningiomas: A Pilot Study

ABSTRACT

Objectives: To present a pilot study of hydroxyurea chemotherapy in the management of surgically difficult meningiomas. Design: Prospective case series. Setting: Tertiary referral center. Participants: Six patients were enrolled: five had symptomatic recurrent or residual WHO Grade I meningiomas and one had an unoperated anterior clinoidal meningioma. Main outcome measures: MRI volumetry before and after treatment, hematological state, progression to surgery. Results: Hydroxyurea was administered for 1 year, starting at a dose of 15 mg/kg/day. No tumors reduced in size on treatment and one continued to grow rapidly. Three remained stable. Full volumetry was unavailable on two patients. One patient was withdrawn from the study because of myelosuppression and underwent further surgery. Three experienced significant drug-related side effects. Two patients underwent further surgery. Conclusions: From this small pilot study we conclude that although hydroxyurea may be associated with disease stabilization in some patients, it did not reduce tumor mass and it caused significant side effects in some of our subjects.

Hydroxyurea - chemotherapy - meningioma

REFERENCES

• 1 Chamberlain M C. Meningiomas.  Curr Treat Options Neurol. 2001;  3 67-76
• 2 Gonzales M F. Classification of brain tumours. In: Kaye AH, Laws ER Brain Tumours. Edinburgh; Churchill Livingstone 1995: 675
• 3 De Monte F. Current management of meningiomas.  Oncology (Williston Park). 1995;  9 83-91, 96 discussion 96, 99-100
• 4 Akeyson E W, McCutcheon I E. Management of benign and aggressive intracranial meningiomas.  Oncology (Williston Park). 1996;  10 747-756 discussion 756-759
• 5 Mason W P, Gentili F, Macdonald D R, Hariharan S, Cruz C R, Abrey L E. Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma.  J Neurosurg. 2002;  97 341-346
• 6 Marks S M, Whitwell H L, Lye R H. Recurrence of meningiomas after operation.  Surg Neurol. 1986;  25 436-440
• 7 Goldsmith B J, Wara W M, Wilson C B, Larson D A. Postoperative irradiation for subtotally resected meningiomas. A retrospective analysis of 140 patients treated from 1967 to 1990.  J Neurosurg. 1994;  80 195-201
• 8 Kondziolka D, Levy E I, Niranjan A, Flickinger J C, Lunsford L D. Long-term outcomes after meningioma radiosurgery: physician and patient perspectives.  J Neurosurg. 1999;  91 44-50
• 9 Grunberg S M, Weiss M H. Lack of efficacy of megestrol acetate in the treatment of unresectable meningioma.  J Neurooncol. 1990;  8 61-65
• 10 Kaba S E, De Monte F, Bruner J M et al.. The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B.  Neurosurgery. 1997;  40 271-275
• 11 Kyritsis A P. Chemotherapy for meningiomas.  J Neurooncol. 1996;  29 269-272
• 12 Schrell U M, Rittig M G, Anders M et al.. Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway.  J Neurosurg. 1997;  86 845-852
• 13 Schrell U M, Rittig M G, Anders M et al.. Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea.  J Neurosurg. 1997;  86 840-844
• 14 Newton H B, Slivka M A, Stevens C. Hydroxyurea chemotherapy for unresectable or residual meningioma.  J Neurooncol. 2000;  49 165-170
• 15 Rosenthal M A, Ashley D L, Cher L. Treatment of high risk or recurrent meningiomas with hydroxyurea.  J Clin Neurosci. 2002;  9 156-158
• 16 Paus S, Klockgether T, Urbach H, Schlegel U. Meningioma of the optic nerve sheath: treatment with hydroxyurea.  J Neurol Neurosurg Psychiatry. 2003;  74 1348-1350